The assistant professor from the University of Michigan talked about personalizing radiation treatment in patients with breast cancer and how genomic signatures can be used to identify the radiation needs of patients.
A panel of experts discussed their institutions’ practices for administering bispecific antibodies, BCMA or GPRC5D, to patients with multiple myeloma.
Treatment with disitamab vedotin and toripalimab improves survival regardless of cisplatin eligibility or HER2 expression level in the phase 3 RC48-C016 trial.
The safety profile of daratumumab plus bortezomib, melphalan, and prednisone remained stable at follow-up, and no new safety signals were observed.
The trial initiation is based on phase 1/2 IDeate-PanTumor01 trial results presented at the 2022 and 2023 European Society for Medical Oncology Congress.
Kit Yu Lu, MD, discusses the applications of T-DXd and sacituzumab govitecan for patients with breast cancer.
CAR T-cell therapies such as liso-cel and axi-cel in DLBCL were the focal points during an Around the Practice program at the 2025 Tandem Meeting.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Shannon L. Puhalla, MD, delves into the clinical application, efficacy, and safety profiles of T-DXd and sacituzumab govitecan for patients with breast cancer.
Teal Wand showed a 95% positive percent agreement when screening for cervical cancer.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
